Edition:
United Kingdom

Novan Inc (NOVN.OQ)

NOVN.OQ on NASDAQ Stock Exchange Global Market

3.13USD
19 Apr 2018
Change (% chg)

-- (--)
Prev Close
$3.13
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
20,614
52-wk High
$7.30
52-wk Low
$2.65

Chart for

About

Novan, Inc. is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs). The Company's... (more)

Overall

Beta: --
Market Cap(Mil.): $85.83
Shares Outstanding(Mil.): 15.98
Dividend: --
Yield (%): --

Financials

  NOVN.OQ Industry Sector
P/E (TTM): -- 30.95 32.74
EPS (TTM): -2.85 -- --
ROI: -214.19 14.84 14.38
ROE: -- 16.34 16.07

BRIEF-Novan Interim CEO Kelly Martin Will No Longer Serve In Interim Capacity

* NOVAN ADVANCES ORGANIZATION AND STRENGTHENS LEADERSHIP TEAM

12 Apr 2018

BRIEF-Eugene Sun Appointed To Novan Board Of Directors

* EUGENE SUN APPOINTED TO NOVAN BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

21 Feb 2018

BRIEF-Novan Announces First Patient Dosed In Phase 2 Molluscum Contagiosum Trial With SB206

* NOVAN ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 MOLLUSCUM CONTAGIOSUM TRIAL WITH SB206

25 Jan 2018

BRIEF-Reedy Creek Investments Reports 26.4 Percent Stake In Novan Inc

* REEDY CREEK INVESTMENTS LLC REPORTS 26.4 PERCENT STAKE IN NOVAN INC AS OF JANUARY 9 - SEC FILING Source text : ( http://bit.ly/2DvfPeF ) Further company coverage:

22 Jan 2018

BRIEF-Novan Says Interim CFO William Hodges To Step Down

* NOVAN INC - WILLIAM L. HODGES, INTERIM CHIEF FINANCIAL OFFICER NOTIFIED THE CO OF HIS DECISION TO STEP DOWN EFFECTIVE JANUARY 19, 2018

19 Jan 2018

BRIEF-Novan Announces Pricing Of $38.0 Mln Offering Of Common Stock And Warrants

* NOVAN ANNOUNCES PRICING OF $38.0 MILLION OFFERING OF COMMON STOCK AND WARRANTS

05 Jan 2018

BRIEF-Novan Announces Proposed Public Offering Of Common Stock And Warrants

* NOVAN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND WARRANTS Source text for Eikon: Further company coverage:

04 Jan 2018

BRIEF-Novan announces first patient dosed in phase 1B Atopic Dermatitis trial With Sb414

* NOVAN ANNOUNCES FIRST PATIENT DOSED IN PHASE 1B ATOPIC DERMATITIS TRIAL WITH SB414

05 Dec 2017

BRIEF-Novan says ‍agreed to business structure to enable development of SB204 via 3rd party financing and execution

* Novan Inc -‍agreed to business structure to enable development of SB204 via 3rd party financing, 3rd party execution of additional Phase 3 pivotal trial​

07 Nov 2017

Earnings vs. Estimates